Cargando…

Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity

Obesity adversely impacts millions of American adults by predisposing them to significant health risks and further complications. Obesity is differentiated into two groups: metabolically healthy and metabolically unhealthy. In contrast to metabolically healthy counterparts, obese individuals who are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmeister, Melissa A., Smith, Tara E., Fincher, Timothy K., Weldon, Abby J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308999/ https://www.ncbi.nlm.nih.gov/pubmed/37396171 http://dx.doi.org/10.3389/fendo.2023.1205490

Ejemplares similares

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
por: Kenngott, S, et al.
Publicado: (2010)

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
por: Sharma, Rakesh K, et al.
Publicado: (2010)

PS212. Effects of Proton Pump Inhibitors (PPI) on the Serum Concentrations of Venlafaxine
por: Paulzen, Michael, et al.
Publicado: (2016)

The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia
por: Tai, Yong Ting, et al.
Publicado: (2020)

Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome
por: Martinez, Jason E., et al.
Publicado: (2021)

Dietary Inulin Fibers Prevent Proton-Pump Inhibitor (PPI)-Induced Hypocalcemia in Mice
por: Hess, Mark W., et al.
Publicado: (2015)

Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified
por: Bruno, Giovanni, et al.
Publicado: (2019)

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
por: Ghebre, Yohannes T.
Publicado: (2020)

Editorial: Metabolically Healthy and Unhealthy Obese Children and Adolescents
por: Chiesa, Claudio, et al.
Publicado: (2020)

Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain
por: Czwornog, Jennifer L., et al.
Publicado: (2015)

Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia
por: Wauters, Lucas, et al.
Publicado: (2021)

Editorial: Metabolically healthy and unhealthy obese children and adolescents, volume II
por: Xi, Bo, et al.
Publicado: (2022)

Prevalence and clinical characteristics of metabolically healthy obese versus metabolically unhealthy obese school children
por: Wan Mohd Zin, Ruziana Mona, et al.
Publicado: (2022)

Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease
por: Shi, Yichao, et al.
Publicado: (2023)

Precocious Preclinical Cardiovascular Sonographic Markers in Metabolically Healthy and Unhealthy Childhood Obesity
por: Corica, Domenico, et al.
Publicado: (2020)

Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
por: Arj, Abbas, et al.
Publicado: (2022)

Effects of Proton Pump Inhibitor Therapy, H. pylori Infection and Gastric Preneoplastic Pathology on Fasting Serum Gastrin Concentrations
por: Veysey-Smith, Reuben, et al.
Publicado: (2021)

Sex differences in metabolically healthy and metabolically unhealthy obesity among Chinese children and adolescents
por: Cai, Shan, et al.
Publicado: (2022)

Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy
por: Nakamura, Kazuhiko, et al.
Publicado: (2016)

Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients
por: Lee, Hee Jeong, et al.
Publicado: (2018)

Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
por: Hojo, Mariko, et al.
Publicado: (2022)

Metabolically Healthy or Metabolically Unhealthy Obese HIV-Infected Patients: Mostly a Matter of Age?
por: Neves, João Sérgio, et al.
Publicado: (2018)

Corrigendum: Sex differences in metabolically healthy and metabolically unhealthy obesity among Chinese children and adolescents
por: Cai, Shan, et al.
Publicado: (2022)

Cardiovascular Risk Factors Associated With the Metabolically Healthy Obese (MHO) Phenotype Compared to the Metabolically Unhealthy Obese (MUO) Phenotype in Children
por: Genovesi, Simonetta, et al.
Publicado: (2020)

Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics
por: Kiecka, Aneta, et al.
Publicado: (2023)

Editorial: Dysbiosis, obesity, and inflammation: interrelated phenomena causes or effects of metabolic syndrome?
por: Wani, Kaiser, et al.
Publicado: (2023)

Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients
por: Lee, Hee Jeong, et al.
Publicado: (2018)

Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle
por: Holly, Jeff M. P., et al.
Publicado: (2020)

Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection
por: Lin, Cheng-Yu, et al.
Publicado: (2022)

Endometriosis and dysbiosis: State of art
por: Zizolfi, Brunella, et al.
Publicado: (2023)

Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility
por: Fossmark, Reidar, et al.
Publicado: (2019)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011
por: Kanerva, M, et al.
Publicado: (2013)

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011)

Diabetic retinopathy risk in patients with unhealthy lifestyle: A Mendelian randomization study
por: Su, Zixuan, et al.
Publicado: (2023)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

An Evidence-Based Retrospective Study for the Management of Acid Peptic Disease With Omeprazole, a Proton Pump Inhibitor, in Indian Patients With Type 2 Diabetes Mellitus (PRIDE-1)
por: Saboo, Bharat, et al.
Publicado: (2022)

Proton Pump Inhibitor Use in the U.S. Ambulatory Setting, 2002–2009
por: Rotman, Stephen R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i432n2bntfug1vu2m9l9sfr7uf